Lyra Therapeutics Q3 net loss narrows
Lyra Therapeutics reported a Q3 2025 net loss of $6.0 million, down from $11.9 million last year. The company plans a new Phase 3 trial for LYR-210, targeting NDA submission, with cash reserves expected to fund operations into Q3 2026. R&D expenses decreased due to the completion of the ENLIGHTEN 2 trial, while G&A expenses were reduced through lower employee costs. Analysts currently rate the stock as a "hold," with a median 12-month price target of $23.00, significantly above its recent closing price of $4.24.
)
Overview
- Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year
- Company plans new Phase 3 trial for LYR-210, aiming for NDA submission
- Cash reserves expected to fund operations into Q3 2026
Outlook
- Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission
- Company anticipates cash reserves to fund operations until Q3 2026
Result Drivers
- R&D EXPENSES - Decrease in R&D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction
- G&A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $25,000
Collabor
ation
Revenue
Q3 EPS -$3.38
Q3 Net -$5.98
Income mln
Analyst Coverage
- The current average analyst rating on the shares is “hold” and the breakdown of recommendations is no “strong buy” or “buy”, 4 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy.”
- Wall Street’s median 12-month price target for Lyra Therapeutics Inc is $23.00, about 81.6% above its November 11 closing price of $4.24
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
